In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 15_suppl ( 2020-05-20), p. 2553-2553
Abstract:
2553 Background: The blockade of lymphocyte-activation gene 3 (LAG-3), an inhibitory receptor on tumor-infiltrating lymphocytes, is currently under investigation in many extracranial tumor entities. Methods: 54 patients with diffuse glioma were included: 35 patients with glioblastoma (GBM, median age at diagnosis: 61 years) as well as 14 with WHO grade II and 5 with WHO grade III glioma (lower-grade glioma, LGG, median age at diagnosis: 45 years). Isocitrate dehydrogenase 1/2 mutations (IDH-mt) were present in 17/54 patients and 37/54 patients had IDH wildtype (IDH-wt) tumors. LAG-3 expression on tumor-infiltrating lymphocytes (TILs) was analyzed by immunohistochemistry (monoclonal anti-LAG-3 antibody, clone 17B4, LSBio Inc.). Results: LAG-3 + TILs could be observed in 5/54 (9.3%) samples, while CD3 + TILs were present in 32/54 (59.3%) and CD8 + TILs in 24/54 (44.4%) samples. Only IDH-wt glioma presented with LAG-3 + TILs (p = 0.168). Samples with LAG-3 + TILs presented with a numerical trend towards higher presence of CD3 + (5/27 CD3 + vs. 0/22 CD3 − , p = 0.072) and CD8 + TILs (4/24 CD8 + vs. 1/30 CD8 − , p = 0.159). 4/7 (57.1%) samples presenting with PD-1 + TILs also presented with LAG-3 + TILs (p = 0.001). Furthermore, glioma samples with LAG3 + TILs presented with higher expression of PD-L1 (median: 1% vs. 0%; p = 0.166). There was no difference in overall survival (OS) according to LAG-3 + TIL infiltration (median OS in LAG-3 + : 21.7 months vs. LAG-3 − : 41.4 months, p 〉 0.05). Conclusions: LAG-3 + TILs are rarely observed in IDH-wt and absent in IDH-mt glioma. Gliomas with an active inflammatory microenvironment present more frequently with LAG3 + TILs. The diverse composition of the inflammatory microenvironment and particular inflammatory subgroups should be considered in future clinical trials on immune-modulating therapies in glioma.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2020.38.15_suppl.2553
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2020
detail.hit.zdb_id:
2005181-5
Bookmarklink